1. Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis 
Rebecca G. Kim, Rohit Loomba, Larry J. Prokop, Siddharth Singh 
Clinical Gastroenterology and Hepatology 
Volume 15, Issue 10, Pages e8 (October 2017)
DOI: /j.cgh
Copyright © 2017 AGA Institute Terms and Conditions

2. Figure 1
Study selection flowsheet. NASH, nonalcoholic steatohepatitis.
Clinical Gastroenterology and Hepatology  , e8DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

3. Figure 2
Forest plot showing the association between statin exposure and risk of progression of fibrosis or development of cirrhosis.
Clinical Gastroenterology and Hepatology  , e8DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

4. Figure 3
Forest plot showing the association between statin exposure and risk of decompensation of cirrhosis. Of note, on restricting analysis only to patients with baseline compensated cirrhosis (excluding patients with noncirrhotic CLDs in Huang et al), a similar protective association between statin use and risk of hepatic decompensation was observed (RR, 0.54; 95% CI, 0.44–0.66).
Clinical Gastroenterology and Hepatology  , e8DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

5. Figure 4
Forest plot showing the association between statin exposure and risk of all-cause mortality. On restricting analysis only to patients with baseline cirrhosis (excluding patients with noncirrhotic CLDs),42 a similar protective association was observed (RR, 0.54; 95% CI, 0.47–0.61), with minimal heterogeneity (I2 = 10%).
Clinical Gastroenterology and Hepatology  , e8DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

6. Figure 5
Forest plot showing the association between statin exposure and risk of progression of portal hypertension.
Clinical Gastroenterology and Hepatology  , e8DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions

7. Supplementary Figure 1
Methodological quality of RCTs. In the Cochrane Risk of Bias tool, studies were deemed to be at high (red), low (green) or unclear (yellow) risk of bias based on adequacy of sequence generation, allocation concealment, blinding, method of addressing incomplete data, selective reporting, and other biases. The review authors’ judgments about each risk of bias item are presented for each included study. +, low risk of bias; ?, unclear risk.
Clinical Gastroenterology and Hepatology  , e8DOI: ( /j.cgh )
Copyright © 2017 AGA Institute Terms and Conditions